Free Trial

Prothena (PRTA) Stock Forecast & Price Target

$21.59
-0.06 (-0.28%)
(As of 05/22/2024 ET)

Prothena - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 7 Analyst Ratings

Consensus Price Target

$67.00
210.33% Upside
High Forecast$87.00
Average Forecast$67.00
Low Forecast$35.00
TypeCurrent Forecast
5/24/23 to 5/23/24
1 Month Ago
4/24/23 to 4/23/24
3 Months Ago
2/23/23 to 2/23/24
1 Year Ago
5/24/22 to 5/24/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
7 Buy rating(s)
8 Buy rating(s)
9 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$67.00$69.63$69.89$86.33
Forecasted Upside210.33% Upside108.36% Upside72.70% Upside54.18% Upside
Get Prothena Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter.

PRTA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PRTA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Prothena Stock vs. The Competition

TypeProthenaMedical CompaniesS&P 500
Consensus Rating Score
2.71
2.69
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside210.33% Upside708.77% Upside8.94% Upside
News Sentiment RatingPositive News
Neutral News
Positive News

Recent Analyst Forecasts and Stock Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/9/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Outperform ➝ Market Outperform$85.00 ➝ $83.00+280.21%
5/9/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$90.00 ➝ $84.00+281.99%
4/10/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight
2/20/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$98.00 ➝ $80.00+185.51%
2/16/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetSector Perform ➝ Sector Perform$36.00 ➝ $35.00+24.33%
1/30/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Neutral$68.00 ➝ $38.00+12.56%
12/12/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$62.00+76.24%
4/24/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Li
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
4/24/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$80.00+46.74%
2/27/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$76.00 ➝ $72.00+31.94%
1/27/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$94.00+68.31%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 02:17 AM ET.

PRTA Frequently Asked Questions

What is Prothena's stock forecast and purchase recommendation?

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Prothena is $67.00, with a high forecast of $87.00 and a low forecast of $35.00. The consensus rating for Prothena stock is Moderate Buy based on the current 2 hold ratings and 5 buy ratings for PRTA. Learn more on PRTA's analyst rating history.

Do Wall Street analysts like Prothena more than its competitors?

Analysts like Prothena more than other "medical" companies. The consensus rating score for Prothena is 2.71 while the average consensus rating score for "medical" companies is 2.69. Learn more on how PRTA compares to other companies.

Does Prothena's stock price have much upside?

According to analysts, Prothena's stock has a predicted upside of 133.42% based on their 12-month stock forecasts.

What analysts cover Prothena?

Prothena has been rated by research analysts at Cantor Fitzgerald, HC Wainwright, and JMP Securities in the past 90 days.


Stock Forecasts and Research Tools

This page (NASDAQ:PRTA) was last updated on 5/23/2024 by MarketBeat.com Staff

From Our Partners